Search Results

1 - 10 of 127 items :

  • Human Biology x
Clear All
Exploring eponyms in a corpus of medical articles. Origins and meanings

References 1. Ma L, Chung KC. In Defense of Eponyms. Plast Reconstr Surg. 2012 May 129(5):896e-898e. DOI: 10.1097/PRS.0b013e31824aa083 2. Ferguson RP, Thomas D. Medical eponyms. J Community Hosp Intern Med Perspect. 2014;4:25046. DOI: 10.3402/jchimp.v4.25046 3. Valderrama-Zurian JC, Melero-Fuentes D, Aleixandre-Benavent R. Origin, characteristics, predominance and conceptual networks of eponyms in the bibliometric literature. Journal of Informetrics. 2019;13:434-48. DOI: 10.1016/j.joi.2019.02.001 4. Thomas PMB. Are medical eponyms really

Open access
Acute effects of recreational soccer on inflammatory response and cardiac and skeletal muscle damage indicators

1;114(11):2289-97. DOI: 10.1007/s00421-014-2953-3 4. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol. 2010 Jul 13;56(3):169-76. DOI: 10.1016/j.jacc.2010.03.037 5. Mehta R, Gaze D, Mohan S, Williams KL, Sprung V, George K, et al. Post-exercise cardiac troponin release is related to exercise training history. Int J Sports Med. 2012 May;33(05):333-7. DOI: 10.1055/s-0031-1301322 6. Knebel F, Schimke I, Schroeckh S, Peters H

Open access
The angiotensinogen gene polymorphism, lifestyle factors, associated diseases and gastric areas of inflammatory and preneoplastic lesions in a Romanian sample of patients

M, Furuta T, Shirai N, Ikuma M, Sugimura H, Hishida A. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol. Biomarkers Prev. 2006 Oct;15(10):1929-1934; DOI: 10.1158/1055-9965.EPI-06-0339 11. Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, et al. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2005 Dec;14(12):2987-9; DOI: 10.1158/1055-9965.EPI-05-0411 12. Perdomo

Open access
The prognostic value of mean platelet volume in cancer patients

-affecting children, unfortunately, approximately 10% of young patients never achieve complete remission [ 32 , 33 ]. In the study of Huang et al. [ 30 ], PLT, MPV, and PCT levels were found to be lower in the ALL group than in the normal and ALL complete remission induced groups ( p < 0.05). Although in other research, the MPV was larger in patients with leukemia (mean ± SD: 8.615 ± 1.59 fL) than in controls group (mean ± SD: 8.355 ± 1.11 fL) at diagnosis, but it was statistically not significant between the two groups ( p = 0.36). Authors suggested that the cause of this was

Open access
Infectious complications in children and adults with hematological malignancies

.3%) as proven/probable IFD, and 39 (6.6%) as VI. Similarly, in 41 (67.2%) patients with rAML disease, 99 EIC were found (2.4 IC per patient), including BI in 78 (78.8%), probable IFD in 14 (14.1%), and VI in 7 (7.1%) cases ( p =0.5). Gram-negative strains were predominant, including multidrug-resistant strains in half of the cases. Characteristics of IFD and VI were comparable for iAML and rAML. Survival of infectious complications . Overall, in iAML group, 10 out of 250 (4.0%) patients died due to EIC: IFD contributed to three deaths, whereas BSI caused by

Open access
Diagnosis and management of complications of chronic lymphocytic leukemia/small lymphocytic lymphoma

, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116:4771-6. 20736453 10.1182/blood-2010-05-286500 Moreno C Hodgson K Ferrer G et al Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance Blood 2010 116 4771 6 [61] Hallek M, Cheson BD, Catovsky D, et al. CLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018

Open access
Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny

D, Smith A, Appleton S, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study. Br J Haematol 2017;177(1):67–71. 28146275 10.1111/bjh.14513 Howell D Smith A Appleton S et al Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study Br J Haematol 2017 177 1 67 71 [6] Lyratzopoulos G, Saunders Cl, Abel GA, et al. The relative length of the patient and the primary care interval in patients with 28 common and

Open access
Rzadkie postacie chłoniaków T-komórkowych – aktualne postępowanie

/mdv201 D’Amore F Galuard P Trupmer L et al Peripheral T cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2015 26 Suppl 5:v 108 15 [4] MD Anderson Cancer Center. Peripheral T-cell Lymphomas (PTCL) practice algorithm. 2017. MD Anderson Cancer Center. Peripheral T-cell Lymphomas (PTCL) practice algorithm 2017 [5] Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756–67. 21493798 10.1182/blood-2010-05-231548 Foss FM Zinzani PL Vose JM et al

Open access
Postępowanie u pacjentek z nowotworem mieloproliferacyjnym BCR-ABL ujemnym w ciąży

otrzymywały LMWH ryzyko VTE w trakcie ciąży wynosiło 2,5% (95% CI, 1,3-4,3), a w okresie połogu 4,4% (95% CI, 1,2-9,5). Uważa się, że ryzyko VTE u zdrowych ciężarnych wynosi 0,1% (5-12/10 000 ciąż) i 0,05% w okresie połogu (3-7/10 000) [ 8 , 9 ]. Przyjmuje się, że korzyść z profilaktyki LMWH odnoszą kobiety, u których ryzyko VTE wynosi ≥ 3%. Autorzy zalecają zatem profilaktykę LMWH w okresie połogu u wszystkich pacjentek z MPN bez przeciwskazań do tej terapii. Chore na MPN narażone są również na większe ryzyko krwawień. W obserwowanej grupie odnotowano 12 epizodów

Open access
Chłoniak z komórek płaszcza – rola terapii celowanych

. Piśmiennictwo/References [1] Martin P, Ghione P, Dreyling M. Mantle cell lymphoma – Current standards of care and future directions. Cancer Treat Rev 2017;58:51-60. 10.1016/j.ctrv.2017.05.008 28651117 Martin P Ghione P Dreyling M Mantle cell lymphoma – Current standards of care and future directions Cancer Treat Rev 2017 58 51 60 [2] Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk- stratification, and clinical management. Am J Hematol 2017;92:806- 13. 28699667 10.1002/ajh.24797 Vose JM Mantle cell lymphoma: 2017 update on

Open access